Akebia Therapeutics (AKBA) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 21.2% versus a loss of 70.4%. Over five years, AKBA leads with a -69.4% price change compared with -82.9% for PYXS. Pyxis Oncology is the larger company by market cap ($236.5 million vs $227.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | PYXS |
|---|---|---|
| Share price | $0.8213 | $1.98 |
| Market cap | $227.59M | $236.52M |
| 1-day change | -5.97% | -1.49% |
| YTD return | -45.75% | +74.78% |
| 1-year return | -70.39% | -21.18% |
| 5-year return | -69.35% | -82.92% |
| EPS (TTM) | $-0.12 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $5.55 |
| 52-week low | $0.814 | $1.03 |
| Distance from 52-week high | -74.33% | -64.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +377.29% | +337.88% |
| Average volume | 6.13M | 1.25M |
| Shares outstanding | 277.11M | 119.46M |
| Employees | 194 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYXS has outperformed AKBA by 49.2 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
AKBA vs PYXS FAQ
Which is bigger, Akebia Therapeutics or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $236.52M compared with $227.59M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or PYXS?
PYXS returned -21.18% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.